Indivior PLC

Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence

by

RICHMOND, Va., June 14, 2023 /PRNewswire/ — Indivior PLC (LSE/Nasdaq: INDV) today announced the acceptance of four abstracts for presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) taking place June 17-21, 2023, in Denver, Colorado. The abstracts cover experiences of patients with cannabis use disorder (CUD) and … Read more

Indivior to Commence Trading on Nasdaq

by

Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment; Company Will Maintain Premium Listing on London Stock Exchange RICHMOND, Va., June 12, 2023 /PRNewswire/ — Indivior PLC (LSE: INDV), a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses, … Read more

Indivior Reaches Agreement with States’ Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims

by

RICHMOND, Va., June 2, 2023 /PRNewswire/ — Indivior PLC (LSE: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the “Company”), has reached an agreement to resolve the claims brought by the Attorneys General of 41 states and the District of Columbia (“the Claimants”) in the In re Suboxone Antitrust Litigation multi-district litigation (“MDL”). … Read more

Indivior Reaches Agreement with States’ Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims

by

RICHMOND, Va., June 2, 2023 /PRNewswire/ — Indivior PLC (LSE: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the “Company”), has reached an agreement to resolve the claims brought by the Attorneys General of 41 states and the District of Columbia (“the Claimants”) in the In re Suboxone Antitrust Litigation multi-district … Read more

Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

by

In the 12-month period ending in December 2022, over 79,000 people in the U.S. were reported to have died of an opioid overdose, of which 90% – approximately 72,000 – were linked to illicit synthetic opioids, mainly fentanyl1 Approval based on data from a pharmacodynamic study demonstrating that OPVEE provides fast onset of reversal of … Read more